OUS
Oslo, Norway
OUS
Oslo, Norway

Time filter

Source Type

Turowski G.,University of Oslo | Berge L.N.,OUS | Helgadottir L.B.,OUS | Jacobsen E.-M.,OUS | And 2 more authors.
Placenta | Year: 2012

Objective: At present there is no internationally accepted, clinically easy understandable, comprehensive morphological placental classification. This hampers international benchmarking and comparisons, and clinical research. Study design: Internationally published criteria on morphological placental pathology were collected, standardized and focused into a comprehensive diagnosis category system. The idea was to create a clinically relevant placental pathology scheme related to major pathological processes. A system of nine main diagnostic categories (normal placenta included) was constructed. Pathologists and obstetricians discussed the mutual understanding of the wording in the reporting. The previously published diagnostic criteria were merged, structured and standardized. Through an interobserver correlation study on 315 placentas from intrauterine deaths and 31 controls (placentas from live births) the microscopic criteria in this classification system were tested on user-friendliness and reproducibility. Results: The clinical feedback has been very positive, focusing on the understandability and usefulness in patient follow-up. The interobserver agreement in the microscopic correlation study was in general good. The differences in agreement mainly reflected the degree of preciseness of the microscopic criteria, exemplified by excellent correlation in diagnosing acute chorioamnionitis. Maternal and fetal circulatory disorders need grading criteria and studies are needed to get more insight and clinical correlations of villitis and maturation disorders. Conclusion: The clinically oriented, unifying and simple placental pathology classification system may work as a platform for standardization and international benchmarking. Further research is needed to define diagnostic criteria in staging and grading of some main diagnostic categories. © 2012 Elsevier Ltd. All rights reserved.


Lau C.,Nordland Hospital | Nygard S.,University of Oslo | Fure H.,Nordland Hospital | Olstad O.K.,OUS | And 11 more authors.
PLoS ONE | Year: 2015

Systemic inflammation like in sepsis is still lacking specific diagnostic markers and effective therapeutics. The first line of defense against intruding pathogens and endogenous damage signals is pattern recognition by e.g., complement and Toll-like receptors (TLR). Combined inhibition of a key complement component (C3 and C5) and TLR-co-receptor CD14 has been shown to attenuate certain systemic inflammatory responses. Using DNA microarray and gene annotation analyses, we aimed to decipher the effect of combined inhibition of C3 and CD14 on the transcriptional response to bacterial challenge in human whole blood. Importantly, combined inhibition reversed the transcriptional changes of 70% of the 2335 genes which significantly responded to heat-inactivated Escherichia coli by on average 80%. Single inhibition was less efficient (p<0.001) but revealed a suppressive effect of C3 on 21% of the responding genes which was partially counteracted by CD14. Furthermore, CD14 dependency of the Escherichia coli-induced response was increased in C5-deficient compared to C5-sufficient blood. The observed crucial distinct and synergistic roles for complement and CD14 on the transcriptional level correspond to their broad impact on the inflammatory response in human blood, and their combined inhibition may become inevitable in the early treatment of acute systemic inflammation. © 2015 Lau et al.


PubMed | Norwegian Computing Center, University of Oslo, University of Tromsø, OUS and 2 more.
Type: Journal Article | Journal: PloS one | Year: 2015

Systemic inflammation like in sepsis is still lacking specific diagnostic markers and effective therapeutics. The first line of defense against intruding pathogens and endogenous damage signals is pattern recognition by e.g., complement and Toll-like receptors (TLR). Combined inhibition of a key complement component (C3 and C5) and TLR-co-receptor CD14 has been shown to attenuate certain systemic inflammatory responses. Using DNA microarray and gene annotation analyses, we aimed to decipher the effect of combined inhibition of C3 and CD14 on the transcriptional response to bacterial challenge in human whole blood. Importantly, combined inhibition reversed the transcriptional changes of 70% of the 2335 genes which significantly responded to heat-inactivated Escherichia coli by on average 80%. Single inhibition was less efficient (p<0.001) but revealed a suppressive effect of C3 on 21% of the responding genes which was partially counteracted by CD14. Furthermore, CD14 dependency of the Escherichia coli-induced response was increased in C5-deficient compared to C5-sufficient blood. The observed crucial distinct and synergistic roles for complement and CD14 on the transcriptional level correspond to their broad impact on the inflammatory response in human blood, and their combined inhibition may become inevitable in the early treatment of acute systemic inflammation.


The purposes of this study were to assess the prevalence of chronic fatigue (CF) in irradiated survivors of non-Hodgkin lymphoma, analyze for associations between hormonal dysfunction and CF, and to investigate the associations between CF and functioning. Invited survivors were all treated with radiation to the head and neck region, with or without additional chemotherapy. The participants (n=98) responded to questionnaires measuring CF, mental distress (HADS), and functioning (SF-36), and had blood drawn for analyses of four hormonal axes. Hormonal status was categorized as normal, hormone dysfunction in one or more axes, or hormone replacement therapy. A total of 29% of the survivors had CF. In multivariate analyses there was an increased risk of CF among survivors with untreated hormone dysfunction (OR 3.87, 95% CI: 1.20-12.51, p=0.02). Survivors on hormone substitution did not have increased risk for CF compared to survivors with normal hormonal status. CF was significantly associated with reduced functioning.


CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application. The 2 year-long pivotal study will involve a minimum of 250 patients in US and OUS centers. The study is aimed to show superiority of the Agili-C™ implant over surgical standard of care, i.e. microfracture and debridement, in the treatment of cartilage/osteochondral defects in both osteoarthritic knees and in knees without degenerative changes, making it the first approved study of such broad indications using a single implant. The study is designed as a prospective, multicenter, open-label, randomized and controlled trial, involving up to 3 lesions in the same joint and with a total treatable area of 1-7cm2. Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. Results of these prior investigations demonstrated the potential for cartilage regeneration and remodeling of the underlying subchondral bone, along with pain and symptom relief. "Pivotal studies performed to date were always focused on small, focal and isolated cartilage lesions in a narrowly defined patient group, which does not represent most of the 'real-life' cases," explains Dr. Ken Zaslav, President of the International Cartilage Repair Society (ICRS) and a member of CartiHeal's Clinical Advisory Board. "Based on the robust clinical data of the Agili-C™ implant, FDA has allowed for the first time, treatment indications ranging from single focal defects to multiple defects in osteoarthritis of the knee, which is what us surgeons see on a daily basis. Moreover, this exciting study will compare two control modes in a single arm: microfracture for the treatment of focal lesions and debridement for patients with osteoarthritis." "Over the last few years we've conducted a series of clinical studies in leading centers to learn which kind of patients can benefit from the Agili-C™ implant," says Nir Altschuler, CartiHeal's founder and CEO.  "Together with our Clinical Advisory Board we designed a study that targets a large patient population who can potentially benefit from this implant. We are very pleased that FDA approved our study design, and believe that the Agili-C™ implant will prove to be an ideal treatment for a variety of cartilage lesions in patients who wish to return to a painless and active lifestyle, and currently don't have good alternatives." CartiHeal, a privately-held medical device company headquartered in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. Backed by extensive pre-clinical and clinical data, its flagship product Agili-C™, an aragonite-based biodegradable scaffold, has been shown to promote restoration of hyaline cartilage and remodeling of its underlying subchondral bone through a natural process, without the use of cells or growth factors. Clinical results in the knee, ankle and big toe demonstrated the potential of significant improvement in pain reduction, as well as reduction in related symptoms - through a simple, single-step implantation procedure. In the United States, the Agili-C is an investigational device that is limited to use in the IDE study.  It is not available for sale.


CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application. The 2 year-long pivotal study will involve a minimum of 250 patients in US and OUS centers. The study is aimed to show superiority of the Agili-C™ implant over surgical standard of care, i.e. microfracture and debridement, in the treatment of cartilage/osteochondral defects in both osteoarthritic knees and in knees without degenerative changes, making it the first approved study of such broad indications using a single implant. The study is designed as a prospective, multicenter, open-label, randomized and controlled trial, involving up to 3 lesions in the same joint and with a total treatable area of 1-7cm2. Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. Results of these prior investigations demonstrated the potential for cartilage regeneration and remodeling of the underlying subchondral bone, along with pain and symptom relief. "Pivotal studies performed to date were always focused on small, focal and isolated cartilage lesions in a narrowly defined patient group, which does not represent most of the 'real-life' cases," explains Dr. Ken Zaslav, President of the International Cartilage Repair Society (ICRS) and a member of CartiHeal's Clinical Advisory Board. "Based on the robust clinical data of the Agili-C™ implant, FDA has allowed for the first time, treatment indications ranging from single focal defects to multiple defects in osteoarthritis of the knee, which is what us surgeons see on a daily basis. Moreover, this exciting study will compare two control modes in a single arm: microfracture for the treatment of focal lesions and debridement for patients with osteoarthritis." "Over the last few years we've conducted a series of clinical studies in leading centers to learn which kind of patients can benefit from the Agili-C™ implant," says Nir Altschuler, CartiHeal's founder and CEO. "Together with our Clinical Advisory Board we designed a study that targets a large patient population who can potentially benefit from this implant. We are very pleased that FDA approved our study design, and believe that the Agili-C™ implant will prove to be an ideal treatment for a variety of cartilage lesions in patients who wish to return to a painless and active lifestyle, and currently don't have good alternatives." CartiHeal, a privately-held medical device company headquartered in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. Backed by extensive pre-clinical and clinical data, its flagship product Agili-C™, an aragonite-based biodegradable scaffold, has been shown to promote restoration of hyaline cartilage and remodeling of its underlying subchondral bone through a natural process, without the use of cells or growth factors. Clinical results in the knee, ankle and big toe demonstrated the potential of significant improvement in pain reduction, as well as reduction in related symptoms - through a simple, single-step implantation procedure. In the United States, the Agili-C is an investigational device that is limited to use in the IDE study.  It is not available for sale.


News Article | December 5, 2016
Site: marketersmedia.com

— Future Market Insights delivers key insights on the global teleradiology services market in a new publication titled “Teleradiology Services Market: Global Industry Analysis and Opportunity Assessment, 2016–2026”. Teleradiology is the practice of interpretation and analysis of medical images by a radiologist who is not present at the site where the images are generated. This service is utilised by hospitals, emergency care centres, telemedicine companies, and other clinics. Teleradiology services enable radiologists to use online services in order to improve patient care and treatment without the need to be physically present on site. In terms of revenue, the global teleradiology services market is projected to register a healthy CAGR of 21.0% over the forecast period (2016 – 2026) and increase 6.7x in terms of revenue between 2016 and 2026. The global teleradiology services market is anticipated to project exponential growth over the next 10 years owing to increasing incidences of chronic diseases such as cancer, tumours, and orthopaedic diseases; increasing geriatric population; and excessive hospitalisations and increasing admittance in ambulatory surgical centres and clinics. Increasing consumer awareness regarding teleradiology and easy accessibility to the technology is another key factor likely to drive the global demand for teleradiology services. However, high cost of technology and services, image transmission issues, dearth of trained radiologists and technicians, and a low awareness in emerging economies is likely to pose major challenges for the growth of the global teleradiology services market. Ongoing trends for teleradiology services driving the global market include service offerings with the latest IT infrastructure including artificial intelligence and algorithms, cloud with low maintenance, and image backup storage. The global teleradiology services market is segmented on the basis of Process Type (Certified Reporting Services Process, Preliminary Reporting); Service Type (Emergency Nighthawk, Day Time Coverage, Subspecialty Reading, Second Opinion, Clinical Trails); Modality (X-Ray Scans, Computerised Tomography (CT) Scans, MRI Scans, Ultrasound Scans, Nuclear Scans, Cardiac Echo, Mammography, Electromammography); and End User (Hospital Pharmacies, Clinics, Ambulatory Surgical Centres, Radiology Centres). Certified Reporting Services Process segment is estimated to account for 62.9% revenue share of the global teleradiology services market by 2016 end Emergency Nighthawk service type segment accounted for 31.6% value share in 2015 and is anticipated to dominate the global teleradiology services market throughout the forecast period Computerised Tomography (CT) Scans modality segment is anticipated to register a CAGR of 23.6% between 2016 and 2026 Hospital Pharmacies end user segment is estimated to account for 39.9% revenue share of the global teleradiology services market by 2016 end The global teleradiology services market is segmented on the basis of region into U.S. and OUS (International) (Latin America, EU5, Rest of Europe, Japan, Asia Pacific Excluding Japan, Rest of the World). The U.S. regional market dominated the global teleradiology services market in revenue terms in 2015 and is projected to account for 41.2% market value share by 2026 end. The EU5 region is expected to be the second most lucrative segment in the global teleradiology services market with a market attractiveness index of 1.3 during the forecast period. The report profiles some of the leading players operating in the global teleradiology services market. Top companies featured in the report include Teleradiology Solutions, Argus Radiology, SRL Diagnostics, USARAD Holdings Inc., Vital Radiology Services, Teleradiology Providers, Telemedicine Clinic, TeleDiagnosys Services Pvt. Ltd, Imaging Advantage, Foundation Radiology Group, Direct Radiology, Imaging On Call LLC, ONRAD Inc., Rays (Envision Healthcare Company), StatRad LLC, ARIS Radiology, NightShift Radiology, Mednax Inc., Alta Vista TeleRadiology, and Quality Nighthawk. These established players are focussed on strategic moves such as new product launches, increasing their distribution channels, and getting into partnerships and agreements with hospitals and specialty clinics to increase the brand awareness of their product. For more information, please visit http://www.futuremarketinsights.com/reports/teleradiology-services-market


News Article | November 22, 2016
Site: www.newsmaker.com.au

Future Market Insights delivers key insights on the global teleradiology services market in a new publication titled “Teleradiology Services Market: Global Industry Analysis and Opportunity Assessment, 2016–2026”. Teleradiology is the practice of interpretation and analysis of medical images by a radiologist who is not present at the site where the images are generated. This service is utilised by hospitals, emergency care centres, telemedicine companies, and other clinics. Teleradiology services enable radiologists to use online services in order to improve patient care and treatment without the need to be physically present on site. In terms of revenue, the global teleradiology services market is projected to register a healthy CAGR of 21.0% over the forecast period (2016 – 2026) and increase 6.7x in terms of revenue between 2016 and 2026. The global teleradiology services market is anticipated to project exponential growth over the next 10 years owing to increasing incidences of chronic diseases such as cancer, tumours, and orthopaedic diseases; increasing geriatric population; and excessive hospitalisations and increasing admittance in ambulatory surgical centres and clinics. Increasing consumer awareness regarding teleradiology and easy accessibility to the technology is another key factor likely to drive the global demand for teleradiology services. However, high cost of technology and services, image transmission issues, dearth of trained radiologists and technicians, and a low awareness in emerging economies is likely to pose major challenges for the growth of the global teleradiology services market. Ongoing trends for teleradiology services driving the global market include service offerings with the latest IT infrastructure including artificial intelligence and algorithms, cloud with low maintenance, and image backup storage. The global teleradiology services market is segmented on the basis of Process Type (Certified Reporting Services Process, Preliminary Reporting); Service Type (Emergency Nighthawk, Day Time Coverage, Subspecialty Reading, Second Opinion, Clinical Trails); Modality (X-Ray Scans, Computerised Tomography (CT) Scans, MRI Scans, Ultrasound Scans, Nuclear Scans, Cardiac Echo, Mammography, Electromammography); and End User (Hospital Pharmacies, Clinics, Ambulatory Surgical Centres, Radiology Centres). The global teleradiology services market is segmented on the basis of region into U.S. and OUS (International) (Latin America, EU5, Rest of Europe, Japan, Asia Pacific Excluding Japan, Rest of the World). The U.S. regional market dominated the global teleradiology services market in revenue terms in 2015 and is projected to account for 41.2% market value share by 2026 end. The EU5 region is expected to be the second most lucrative segment in the global teleradiology services market with a market attractiveness index of 1.3 during the forecast period. The report profiles some of the leading players operating in the global teleradiology services market. Top companies featured in the report include Teleradiology Solutions, Argus Radiology, SRL Diagnostics, USARAD Holdings Inc., Vital Radiology Services, Teleradiology Providers, Telemedicine Clinic, TeleDiagnosys Services Pvt. Ltd, Imaging Advantage, Foundation Radiology Group, Direct Radiology, Imaging On Call LLC, ONRAD Inc., Rays (Envision Healthcare Company), StatRad LLC, ARIS Radiology, NightShift Radiology, Mednax Inc., Alta Vista TeleRadiology, and Quality Nighthawk. These established players are focussed on strategic moves such as new product launches, increasing their distribution channels, and getting into partnerships and agreements with hospitals and specialty clinics to increase the brand awareness of their product.


News Article | December 7, 2016
Site: globenewswire.com

PORTLAND, Ore., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Stanley Myers, MD, urologist at Northwest Urology, has partnered with HIFU Prostate Services, LLC (HPS), the leading provider of HIFU technology to urology practices in the United States, to make HIFU for prostate cancer available in Portland, Oregon. Dr. Myers is the leading HIFU physician in the Pacific Northwest and has treated men outside the country with HIFU for nearly six years prior to FDA-clearance of the Sonablate® HIFU technology.  HIFU, which stands for high intensity focused ultrasound, is a non-surgical, radiation-free, outpatient procedure that uses focused sound waves to heat and destroy tissue in the prostate gland. Dr. Myers will offer men with localized prostate cancer HIFU with the Sonablate®, the leading HIFU device for prostate ablation. The FDA cleared the Sonablate® technology for the ablation of prostatic tissue in October 2015. No other HIFU prostate treatment device offers revolutionary features that enhance treatment customization and patient safety. These Sonablate features include software that monitors changes in tissue, can locate and spare nerves responsible for preserving potency and incorporates MRI images into live ultrasound images. Dr. Myers is a certified diplomat of the American Board of Urology who was initially certified in 1999 and recertified in 2006 and 2016. He served as president of the Oregon Urological Society (OUS) from 2012 to 2014 and currently serves on the OUS board as past president. “I am very excited to be able to offer HIFU right here in the Pacific Northwest. This will give patients a minimally invasive treatment option for prostate cancer,” said Dr. Myers. "It has been my pleasure to work with Dr. Stan Myers over the last four years in the development of HIFU for use in the Pacific Northwest. Dr. Myers is a very talented surgeon and HIFU practitioner; his establishing this HIFU center will greatly benefit the region," said Michael Lazar, MD, medical director of HIFU Prostate Services. John Linn, chief executive officer of HIFU Prostate Services said, “We only work with the most experienced urologists who are committed to adding HIFU to the list of options that they offer their patients for localized prostate cancer. Dr. Myers is on the forefront of prostate cancer care and we are excited to work with him and his team.” About HIFU Prostate Services, LLC HIFU Prostate Services (HPS) was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate® HIFU. The company is headquartered in Charlotte, NC. Learn more at http://www.hifuprostateservices.com. ­About Northwest Urology Northwest Urology is dedicated to providing the highest quality urologic care to our patients. Our experienced team of physicians are leaders in HIFU, laparoscopic and robotic surgery, and specialize in the full spectrum of urologic services, from general adult urology, to oncologic urology, to pediatric urology. For more than 40 years, Northwest Urology has been providing the Portland area with the highest standard of adult urological care from simple to complex. We have built on a history of regional leadership and innovation, gaining the reputation of being the place to turn to for the difficult or unusual cases. Learn more at http://nwurology.com.


News Article | December 7, 2016
Site: globenewswire.com

PORTLAND, Ore., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Stanley Myers, MD, urologist at Northwest Urology, has partnered with HIFU Prostate Services, LLC (HPS), the leading provider of HIFU technology to urology practices in the United States, to make HIFU for prostate cancer available in Portland, Oregon. Dr. Myers is the leading HIFU physician in the Pacific Northwest and has treated men outside the country with HIFU for nearly six years prior to FDA-clearance of the Sonablate® HIFU technology.  HIFU, which stands for high intensity focused ultrasound, is a non-surgical, radiation-free, outpatient procedure that uses focused sound waves to heat and destroy tissue in the prostate gland. Dr. Myers will offer men with localized prostate cancer HIFU with the Sonablate®, the leading HIFU device for prostate ablation. The FDA cleared the Sonablate® technology for the ablation of prostatic tissue in October 2015. No other HIFU prostate treatment device offers revolutionary features that enhance treatment customization and patient safety. These Sonablate features include software that monitors changes in tissue, can locate and spare nerves responsible for preserving potency and incorporates MRI images into live ultrasound images. Dr. Myers is a certified diplomat of the American Board of Urology who was initially certified in 1999 and recertified in 2006 and 2016. He served as president of the Oregon Urological Society (OUS) from 2012 to 2014 and currently serves on the OUS board as past president. “I am very excited to be able to offer HIFU right here in the Pacific Northwest. This will give patients a minimally invasive treatment option for prostate cancer,” said Dr. Myers. "It has been my pleasure to work with Dr. Stan Myers over the last four years in the development of HIFU for use in the Pacific Northwest. Dr. Myers is a very talented surgeon and HIFU practitioner; his establishing this HIFU center will greatly benefit the region," said Michael Lazar, MD, medical director of HIFU Prostate Services. John Linn, chief executive officer of HIFU Prostate Services said, “We only work with the most experienced urologists who are committed to adding HIFU to the list of options that they offer their patients for localized prostate cancer. Dr. Myers is on the forefront of prostate cancer care and we are excited to work with him and his team.” About HIFU Prostate Services, LLC HIFU Prostate Services (HPS) was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate® HIFU. The company is headquartered in Charlotte, NC. Learn more at http://www.hifuprostateservices.com. ­About Northwest Urology Northwest Urology is dedicated to providing the highest quality urologic care to our patients. Our experienced team of physicians are leaders in HIFU, laparoscopic and robotic surgery, and specialize in the full spectrum of urologic services, from general adult urology, to oncologic urology, to pediatric urology. For more than 40 years, Northwest Urology has been providing the Portland area with the highest standard of adult urological care from simple to complex. We have built on a history of regional leadership and innovation, gaining the reputation of being the place to turn to for the difficult or unusual cases. Learn more at http://nwurology.com.

Loading OUS collaborators
Loading OUS collaborators